Equity markets rebounded from Wednesdayâs Fed-induced sell-off, but Thursdayâs action gives little reason to think the selling is over. The S&P gained less than 1% to trade in the lower half of the previous dayâs range, creating a Harami candle pattern signaling the sell-off has the potential to gain strength. A move to retest Wednesdayâs low is likely, and a move to new lows is possible. The market could fall as low as 5,700 in that scenario before the S&P 500 hits firm support.
Today will be a test for the market. The PCE Price Index is due and expected to confirm inflation is rising. A hot report will strengthen the Fedâs resolve, possibly leading them to reduce the rate cut outlook again and give the market a reason to sell. The silver lining is that the underlying causes of high inflation are demand and economic health, which are drivers of corporate earnings and bullish for stocks.
As years go by, 2024 has not been a great one for shares of SolarEdge Technologies Inc (NASDAQ: SEDG). The $800 million market cap stock is down 85% since the start of January, which means itâs back trading at 2016 levels. For any investor that was involved in SolarEdge in the 8 years sâŚ
Palantir Technologies Inc. (NASDAQ: PLTR)stock is flat in the four days after the company was named to be part of the NASDAQ 100 starting on December 23, 2024. But thatâs because of a pullback of over 5%, which correlates to the broader market pullback after the Federal Reserveâs decision on iâŚ
Global shares were mostly lower Friday as markets awaited U.S. personal spending data for November that are due later in the day. Britainâs FTSE 100 lost 0.3% to 8,078.21 and the CAC 40 in Paris fell 0.9% to 7,226.70. Germanyâs DAX was 0.9% lower to 19,780.63.The future for the S&P 500 slipped 0âŚ
The smooth economy that Donald Trump was poised to inherit suddenly looks a bit rockier â with critics saying the president-elect is contributing to the uncertainty.The Dow Jones stock index essentially ended Thursday flat after having posted 10 days of losses. The Federal Reserve now sees inflationâŚ
In the midst of companies looking to implement AI and investors looking for a way to profit from the trend, up-and-coming AI firms continue to pop up. Below, Iâll detail three small-cap AI stocks to watch out for in 2025. Two have had great 2024s and are looking to continue their strong showinâŚ
Investors interested in Micron Technology (NASDAQ: MU) should cheer the fact that its stock tanked following the FQ1 2025 earnings report. The move is a knee-jerk reaction to mixed results and guidance that point to near-term weakness and long-term strength, driven by its shift to AI. The lâŚ
Russiaâs central bank has left its benchmark interest rate at 21%, holding off on further increases as it struggles to snuff out inflation fueled by the governmentâs spending on the war against Ukraine
Advertising is an age-old industry that is growing at a brisk pace to this day. GroupM, a market intelligence firm, projects global ad revenues will rise by nearly 10% in 2024. Moreover, it predicts that total revenue will eclipse the $1 trillion mark this year. A key factor contributing to the stâŚ
Lamb Weston, a major supplier of frozen French fries to global chains like McDonaldâs, KFC and Taco Bell, has named a new CEO after posting a surprise loss in the second quarter as consumers pull back on the money they spend on food outside the home
The American economy grew at a healthy 3.1% annual clip from July through September, propelled by vigorous consumer spending and an uptick in exports, the government said in an upgrade to its previous estimate
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a BiâŚ
The Early Bird is a daily email newsletter powered by MarketBeat that covers the top stories that will impact the stock market each day. Read your copy every morning at 7:00 AM Eastern so that you can âcatch the wormâ when the market opens.
MarketBeat Media, LLC
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. contact@marketbeat.com
